A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
复制标题
DOI：
10.1016/s2352-3018(21)00073-4
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Kim JH
中科院分区：
文献类型：
--
作者：
Zolla-Pazner S;Michael NL;Kim JH
在南非（HVTN 702）和泰国（RV 144）进行的艾滋病毒预防疫苗高级阶段试验都研究了金丝雀痘载体和辅助gp120蛋白，得出了不同的结果。南非试验没有发现疫苗的有效性，而泰国试验在两项研究方案中预先规定的改良意向治疗分析中取得了适度但具有统计学意义的成功。需要了解研究之间的差异，以避免可能但错误的结论，即南非试验的结果对泰国试验的结果产生负面影响。
The advanced-phase HIV prevention vaccine trials done in South Africa (HVTN 702) and in Thailand (RV144), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results. The South African trial did not find vaccine efficacy, whereas the Thai trial had modest, but statistically significant, success with the modified intention-to-treat analysis prespecified in the protocols of both studies. An understanding of the differences between the studies is required to avoid the possible, but erroneous, conclusion that the results from the South African trial negatively affect the results of the Thai trial.